Polymeric Nanocarriers of a Monosubstituted Tetraphenylporphyrin Sensitizer Intended for Photodynamic Therapy and Tumor Imaging

To effectively combat advanced cancers, next-generation nanomedicines should combine both therapeutic and diagnostic functions. In this study, we developed stimulus-responsive theranostics systems based on micellar nanostructures that deliver derivatives of tetraphenylporphyrins (TPP) bound via tumor microenvironment-sensitive hydrazone bonds. These nanomedicines are engineered using a micelle-forming polymer-TPP conjugate, enabling the pH-sensitive activation of both photodynamic therapy (PDT) and fluorescence. Two pH-sensitive and one stable polymer-TPP conjugates were synthesized and characterized by size exclusion chromatography and TPP release rates. Micelle stability was evaluated using UV/vis spectroscopy, while fluorescence and singlet oxygen production were measured to determine their theranostics potential. Femtosecond transient absorption and time-correlated single photon counting techniques were employed for the photophysical evaluation of micellar systems. Compared to polymer conjugates where TPP is linked through nondegradable amide bonds, the pH-sensitive systems exhibit superior physicochemical properties. These micellar conjugates are highly stable, allowing prolonged circulation in the body while remaining in an “off” state, where fluorescence and singlet oxygen production are minimized. Overall, the hydrazone-linked conjugates display favorable properties that make them strong candidates for future anticancer theranostic applications.

• Publication year

  2025

• Venue

  ACS Omega

• Publication date

  2025-11-09

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/acsomega.5c07910PMID 41322635PMCID 12658679
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fluorescence lifetime imaging and phasor analysis of intracellular porphyrinic photosensitizers applied with different polymeric formulations.

  2024cited by this paper
• Clinical and pre-clinical advances in the PDT/PTT strategy for diagnosis and treatment of Cancer.

  2024cited by this paper
• Trial watch: an update of clinical advances in photodynamic therapy and its immunoadjuvant properties for cancer treatment

  2023cited by this paper
• Photodynamic therapy based on porphyrin-based metal-organic frameworks.

  2023cited by this paper
• Polymer theranostics with multiple stimuli-based activation of photodynamic therapy and tumor imaging

  2023cited by this paper
• Photodynamic Therapy for Peripheral Lung Cancer.

  2022cited by this paper
• Inner Filter Effect Correction for Fluorescence Measurements in Microplates Using Variable Vertical Axis Focus

  2022cited by this paper
• Comprehensive review of photophysical parameters (ε, Φf, τs) of tetraphenylporphyrin (H2TPP) and zinc tetraphenylporphyrin (ZnTPP) – Critical benchmark molecules in photochemistry and photosynthesis

  2021cited by this paper
• Inverse heavy-atom effect in near infrared photoluminescent gold nanoclusters.

  2021cited by this paper
• Photodynamic Therapy Review: Principles, Photosensitizers, Applications, and Future Directions

  2021cited by this paper
• Photodynamic Therapy—Current Limitations and Novel Approaches

  2021cited by this paper
• An update in clinical utilization of photodynamic therapy for lung cancer

  2021cited by this paper
• Styrene Maleic Acid Copolymer-Based Micellar Formation of Temoporfin (SMA@ mTHPC) Behaves as A Nanoprobe for Tumor-Targeted Photodynamic Therapy with A Superior Safety

  2021cited by this paper
• Current Limitations and Recent Progress in Nanomedicine for Clinically Available Photodynamic Therapy

  2021cited by this paper
• From Basic Mechanisms to Clinical Research: Photodynamic Therapy Applications in Head and Neck Malignancies and Vascular Anomalies

  2021cited by this paper
• Porphyrin and phthalocyanine photosensitizers designed for targeted photodynamic therapy of colorectal cancer.

  2020cited by this paper
• Drug Delivery with Polymeric Nanocarriers—Cellular Uptake Mechanisms

  2020cited by this paper
• Inner filter effect in fluorescence spectroscopy: As a problem and as a solution

  2019cited by this paper
• Cell death in photodynamic therapy: From oxidative stress to anti-tumor immunity.

  2019cited by this paper
• Photosensitizers for Photodynamic Therapy

  2019cited by this paper
• N‐(2‐hydroxypropyl)methacrylamide polymer conjugated pyropheophorbide‐a, a promising tumor‐targeted theranostic probe for photodynamic therapy and imaging

  2018cited by this paper
• A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF‐200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy

  2018cited by this paper
• Adjuvant photodynamic therapy in head and neck cancer after tumor‐positive resection margins

  2018cited by this paper
• Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.

  2017cited by this paper
• HPMA Copolymer-Conjugated Pirarubicin in Multimodal Treatment of a Patient with Stage IV Prostate Cancer and Extensive Lung and Bone Metastases

  2016cited by this paper
• Nanotechnology-Based Drug Delivery Systems for Photodynamic Therapy of Cancer: A Review

  2016cited by this paper
• Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity.

  2015cited by this paper
• Drug Carrier for Photodynamic Cancer Therapy

  2015cited by this paper
• Synthesis of poly[N-(2-hydroxypropyl)methacrylamide] conjugates of inhibitors of the ABC transporter that overcome multidrug resistance in doxorubicin-resistant P388 cells in vitro.

  2014cited by this paper
• Micelles of zinc protoporphyrin conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer for imaging and light-induced antitumor effects in vivo.

  2013cited by this paper
• HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity.

  2012cited by this paper
• Porphyrins as Theranostic Agents from Prehistoric to Modern Times

  2012cited by this paper
• Photosensitizer Radachlorin®: Skin cancer PDT phase II clinical trials.

  2010cited by this paper
• Photodynamic therapy of head and neck cancers.

  2010cited by this paper
• Photodynamic therapy for prostate cancer—a review of current status and future promise

  2009cited by this paper
• Effect of zinc insertion and hydrophobicity on the membrane interactions and PDT activity of porphyrin photosensitizers

  2009cited by this paper
• Stereogradient polymers formed by controlled/living radical polymerization of bulky methacrylate monomers.

  2009cited by this paper
• Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.

  2009cited by this paper
• Light-Induced Electron Transfer of a Supramolecular Bis(Zinc Porphyrin)−Fullerene Triad Constructed via a Diacetylamidopyridine/Uracil Hydrogen-Bonding Motif

  2007cited by this paper
• Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer

  2006cited by this paper
• Exploiting the enhanced permeability and retention effect for tumor targeting.

  2006cited by this paper
• Photophysical properties of porphyrinoid sensitizers non-covalently bound to host molecules; models for photodynamic therapy

  2004cited by this paper
• Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization.

  2004cited by this paper
• Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung.

  2003cited by this paper
• Ultrafast Dynamics of Porphyrins in the Condensed Phase: I. Free Base Tetraphenylporphyrin †

  2002cited by this paper
• Ultrafast Dynamics of Porphyrins in the Condensed Phase:  II. Zinc Tetraphenylporphyrin†.

  2002cited by this paper
• Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study.

  2002cited by this paper
• State of the art in the delivery of photosensitizers for photodynamic therapy.

  2002cited by this paper
• New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties.

  2001cited by this paper
• Photodynamic Therapy of Skin Cancers: Sensitizers, Clinical Studies and Future Directives

  2000cited by this paper
• Effect of zeolite properties on ground-state and triplet-triplet absorption, prompt and oxygen induced delayed fluorescence of tetraphenylporphyrin at gas/solid interface.

  2000cited by this paper
• Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physico-chemical characterisation.

  2000cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper
• Some observations on the chemistry of KO2—DMSO solutions

  1981cited by this paper

• No citing papers are available for this paper.